spacer
home > ict > summer 2018 > restricting remedies
PUBLICATIONS
International Clinical Trials

Restricting Remedies

Herbal medicine has been practised in many countries for centuries. The 2004 European Traditional Herbal Medicinal Products Directive took full effect in the UK in 2011. This legislation effectively banned the importation and sale of large-scale manufactured herbal medicine products and severely limited the scope of some herbal practitioners to continue practising. At present, under UK law, a herbal practitioner is permitted to see individual patients, offer diagnoses, and prepare herbal treatments on their own premises, as long as these preparations do not contain banned or restricted substances. Thus, where ‘herbal’ products derived from the cannabis plant are concerned because they are banned or restricted substances, they cannot be prescribed by herbal practitioners. Herein lies the problem of the use of cannabis oil for the treatment of rare forms of childhood epilepsy, which has gripped the media of late.

In a review into cannabis-related medicinal products, the UK’s Chief Medical Officer and Advisor, Professor Dame Sally Davies, has concluded that evidence shows the therapeutic benefit of cannabis-based medicines for some conditions. The finding has prompted Home Secretary Sajid Javid to commission the second part of the UK’s review into cannabisrelated medicinal products, led by an independent advisory committee. However, prior to this review, cannabis oil had been prescribed to a young boy with epilepsy on the NHS. Reports have called this the “first case of its kind” in the UK.

Cannabis oil is a medicine containing a part of the cannabis plant called cannabidiol (CBD). It does not contain the ‘psychoactive’ part of cannabis – the part that causes the feeling of being high. Last year, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) classed CBD as a medicine in the UK and not a herbal. The agency has thus said that CBD products are required to be licensed, meaning they “have to meet safety, quality and efficacy standards,” as would be the case for any therapeutic drug prescribed in the UK.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer

Print this page
Send to a friend
Privacy statement
News and Press Releases

Packline Materials Handling Announce The Production Of The New Clamp Attachment With Narrow Rollers And Extended Reach For Handling Rolls.

New to Packline Materials Handling is the clamp attachment with motorised rotation, narrow rollers and extended reach, designed to load and unload rolls of film or foil from a pallet and load them into a wrapping machine. This roll handling solution is suitable for food processing and pharmaceutical industries.
More info >>

White Papers

The Importance of ADCC in Assessing Clinically Relevant Differences

Sartorius Stedim BioOutsource Ltd

Biosimilars have caused a revolution in the development of biologic drugs. The model for biosimilars is a combination of speed to market and low cost; these are fundamental to any biosimilar development project. The biosimilars pathway to approval is not always without difficulty, biosimilars are still relatively new, and as each new applicant is reviewed we are learning more and more about these molecules.
More info >>

 
Industry Events

World Advanced Therapies & Regenerative Medicine Congress 2019

15-17 May 2019, Business Design Centre, London

The World Advanced Therapies & Regenerative Medicine Congress is an exhibition and conference that has grown to become one of the best and most established cell and gene events in the world today.     The 2019 edition will be in its 14th year and it continues to grow and attract a large audience of biotech, pharma, start-ups, investors, research and technology companies from around the world. The conference and exhibition will host over 1000 attendees, 250 speakers and 80 exhibition booths. Over 500 different global companies are represented every year at this event. 
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement